C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

2.950 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about C4 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines

January 09, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From C4 Therapeutics, Inc.

Via GlobeNewswire

Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday's Mid-Day Session ↗

November 25, 2022

Gainers Peak Bio, Inc. (NYSE: PKBO) shares jumped 49.1% to $7.08.

Via Benzinga

C4 Therapeutics's Return On Capital Employed Overview ↗

November 23, 2022

Via Benzinga

C4 Therapeutics: Q3 Earnings Insights ↗

November 03, 2022

C4 Therapeutics (NASDAQ:CCCC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Recap: C4 Therapeutics Q2 Earnings ↗

August 04, 2022

C4 Therapeutics (NASDAQ:CCCC) reported its Q2 earnings results on Thursday, August 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗

December 19, 2022

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

Via Benzinga

US Stocks Mixed On Black Friday; Dow Rises Over 100 Points ↗

November 25, 2022

U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 100 points on Friday. Equity markets will close early on Black Friday, the day after Thanksgiving.

Via Benzinga

C4 Therapeutics: Q1 Earnings Insights ↗

May 05, 2022

C4 Therapeutics (NASDAQ:CCCC) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Where C4 Therapeutics Stands With Analysts ↗

April 28, 2022

Within the last quarter, C4 Therapeutics (NASDAQ:CCCC) has observed the following analyst ratings:

Via Benzinga

Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday ↗

November 25, 2022

Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share.

Via Benzinga

Credit Suisse, Autodesk And Other Big Losers From Wednesday ↗

November 25, 2022

U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points. Here is the list of some big stocks recording losses in the previous session.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 24, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022 ↗

November 04, 2022

Upgrades

Via Benzinga

C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

November 03, 2022

From C4 Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗

October 11, 2022

Upgrades

Via Benzinga

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

September 29, 2022

Phase 1/2 Clinical Trial Will Study CFT1946 in BRAF-V600 Mutant Solid Cancers Including Lung, Colorectal and Melanoma; Trial Initiation Expected by Year End 2022

From C4 Therapeutics, Inc.

Via GlobeNewswire

C4 Therapeutics's Return On Capital Employed Insights ↗

August 22, 2022

According to Benzinga Pro data, during Q2, C4 Therapeutics (NASDAQ:CCCC) posted sales of $13.83 million. Earnings were up 13.31%, but C4 Therapeutics still reported an overall loss of $27.41 million.

Via Benzinga

C4 Therapeutics's Return On Capital Employed Overview ↗

May 27, 2022

C4 Therapeutics (NASDAQ:CCCC) brought in sales totaling $7.65 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 101.94%, resulting in a loss of $31.62 million.

Via Benzinga

C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers ↗

May 16, 2022

C4 Therapeutics, Inc. (C4T) (NASDAQ: CCCC) has dosed the first patient in the Phase 1/2 clinical trial of its drug candidate CFT8634, for the treatment of SMARCB1-perturbed cancers, including synovial...

Via Benzinga

Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday ↗

September 19, 2022

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.

Via Benzinga

66 Biggest Movers From Yesterday ↗

May 03, 2022

Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged...

Via Benzinga

31 Stocks Moving In Monday's Mid-Day Session ↗

May 02, 2022

Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) climbed 64.9% to $9.86. Redbox recently reported CFO transition. SoundHound AI, Inc. (NASDAQ: SOUN) shares gained 30.5% to $8.48...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2022 ↗

April 28, 2022

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 19, 2022

Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) shares increased by 331.5% to $10.4 during Tuesday's pre-market session. The market value of their outstanding shares...

Via Benzinga

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More ↗

April 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

BMO Capital Maintains Outperform Rating for C4 Therapeutics, Lowers Price Target To $20 ↗

April 11, 2022

BMO Capital has decided to maintain its Outperform rating of C4 Therapeutics (NASDAQ:CCCC) and lower its price target from $57.00 to $20.00. Shares of C4 Therapeutics are trading down 20.49% over the...

Via Benzinga

The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More ↗

April 10, 2022

Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.

Via Benzinga

Why C4 Therapeutics Stock Is Plunging Today ↗

April 08, 2022

C4 Therapeutics Inc (NASDAQ: CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongoing Phase 1/2 clinical...

Via Benzinga

C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial ↗

April 08, 2022

C4 Therapeutics Inc (NASDAQ: CCCC) has presented data from Cohort A of its ongoing Phase 1/2 trial of CFT7455 for multiple myeloma (MM) and non-Hodgkin's lymphomas (NHL).

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.